A bayesian reanalysis of the phase III aducanumab (ADU) trial

Tommaso Costa, Franco Cauda

In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Su…